Cyllene Therapeutics adds board and executive hires as EG110A nears late-stage development

The company named Alyssa Levin to its Board and Audit Committee chair role, while Clara Cambon-Thiebaud and Céline Breda joined regulatory and CMC leadership posts.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.